Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.80 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 3.60 | 4.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 3.19M | -6.49M | -0.0122 | -3.11 | 20.27M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 3.80 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 07/11/2024 | 07:01 | UK RNS | Eden Research plc Trading Update |
| 07/11/2024 | 07:00 | UK RNS | Eden Research plc Ecovelex Approval in Italy |
| 08/10/2024 | 10:24 | UK RNS | Eden Research plc OTCQB exchange update |
| 23/9/2024 | 12:15 | ALNC |  Eden Research half-year revenue surges nearly 75% despite rising costs |
| 23/9/2024 | 06:00 | UK RNS | Eden Research plc Half yearly Report |
| 20/9/2024 | 06:00 | UK RNS | Eden Research plc Notice of Results |
| 02/9/2024 | 06:00 | UK RNS | Eden Research plc Nematicide Approval in Greece |
| 15/8/2024 | 06:00 | UK RNS | Eden Research plc Appointment of new Head of Regulatory Affairs |
| 13/8/2024 | 13:16 | ALNC | Eden Research hails approval of biofungicide Mevalone in Germany |
| 13/8/2024 | 06:00 | UK RNS | Eden Research plc Biofungicide regulatory authorisation in Germany |
Eden Research (EDEN) Share Charts1 Year Eden Research Chart |
|
1 Month Eden Research Chart |
Intraday Eden Research Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 21/11/2024 | 00:00 | Eden Research | 19,238 |
| 08/2/2024 | 07:42 | Eden....Onward and Upwards! | 52 |
| 21/6/2023 | 11:05 | The sterile garden of Eden | 123 |
| 29/3/2022 | 15:04 | Eden Research | 14 |
| 29/3/2022 | 13:36 | Eden Research - Who Is Behind Thallo Eco Products Corp? | 27 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-11-20 16:23:45 | 3.80 | 130,000 | 4,940.00 | O |
| 2024-11-20 14:35:43 | 3.76 | 100,000 | 3,760.00 | O |
| 2024-11-20 13:58:15 | 3.78 | 39,683 | 1,500.02 | O |
| 2024-11-20 13:23:43 | 3.88 | 12,731 | 493.96 | O |
| 2024-11-20 13:02:48 | 3.90 | 2,667 | 104.01 | O |
| Top Posts |
|---|
Posted at 20/11/2024 08:20 by Eden Research Daily Update Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 3.80p.Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £20,267,396. Eden Research has a price to earnings ratio (PE ratio) of -3.11. This morning EDEN shares opened at - |
Posted at 10/11/2024 08:22 by supersonico Stone Fruits;"There is significant future potential to expand the use of Mevalone for the treatment of powdery and downy mildews and field trials for these applications on grapes are currently underway, with the potential to expand further to include crops such as berries and stone fruits. All expanded uses of Mevalone are, as always, subject to regulatory approval, which is anticipated in the coming years" .................... Investingisatrickyga It does imply that this approval will lead to other regulators viewing this and actioning the same. I'm looking at Almonds in California! Investingisatrickyga California produces 80% of the world's Almonds and is 100% of US production. Californian Almond crop production is expected to be 21% higher in 2024 over 2023. Almonds are California's 3rd most valuable crop. I fully expect Sipcam to get that label extension. .................... Biofungicide Label Extension in Spain 24 June 2024 This newly expanded label makes Araw one of the most versatile and reliable solutions to prevent fungal diseases in many crops under organic and conventional agriculture. Thanks to this new authorisation, obtained through Sipcam's local regulatory team, all relevant horticultural crops in Spain can now be protected with Araw representing an excellent opportunity in several crops of growing importance, such as avocado, mango, and almond, which has become the third largest tree crop in Spain after olives and grapes. Spain boasts the largest cultivated area of almond trees in the world and ranks third in terms of overall production. Eden anticipates that this growth of the addressable market for Araw will contribute to revenue in 2025 and beyond. Further details of this expansion will be provided in due course as commercialisation commences. Sean Smith, Chief Executive Officer of Eden Research, commented: "Today's announcement is an excellent demonstration of our strategy to pursue growth opportunities through both new product introductions and with existing products by targeting new crop types and new disease targets. We are delighted to build on the success of our longstanding relationship with Sipcam. They have done an outstanding job of making the Iberian region an important and strong revenue-generating territory for the Company. This label extension represents a significant additional growth opportunity for us. It not only includes numerous new crops and diseases, but it also includes a number of high-value crops that are particularly disease prone." |
Posted at 10/11/2024 08:14 by supersonico 15 December 2022Eden Research Plc ("Eden" or "Company") Distribution Agreement for Mevalone in France Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, announces that it has signed an agreement ("Agreement") with Corteva France ("Corteva") which allows Corteva to market, distribute and sell Eden's fungicide product, Mevalone®, in France on an exclusive basis. Mevalone is Eden's flagship, sustainable, foliar biofungicide, which is used to treat Botrytis cinerea on grapes and various other crops, a fungal disease commonly found in crops exposed to humid conditions. Eden also recently received authorisation for the use of Mevalone on pome fruits, including apples and pears, in France to help treat post-harvest diseases that arise during storage, thereby significantly reducing food waste. .................... There is significant future potential to expand the use of Mevalone for the treatment of powdery and downy mildews and field trials for these applications on grapes are currently underway, with the potential to expand further to include crops such as berries and stone fruits. All expanded uses of Mevalone are, as always, subject to regulatory approval, which is anticipated in the coming years. .................... France is widely recognised for its agricultural output, which is well-known for its high quality. France's vineyards are the country's biggest consumers of plant protection products, which include fungicides, insecticides, and herbicides. Although viticulture represents just 3% of France's agricultural land, the sector consumes 20% of the country's fungicides. It also represents 15% of French agricultural produce in value terms; an exciting landscape in which Eden's biopesticides will play an expanded role. The Agreement with Corteva will be implemented immediately with commercial progress expected over the course of the next year as Eden transitions from its current distribution arrangements. Sean Smith, CEO of Eden Research plc, commented: "Expanding our partnership with agriscience powerhouse Corteva reflects the further execution and acceleration of Eden's commercial strategy. Eden has a strong existing partnership with Corteva with our ongoing collaboration around the development of seed treatments, and this Agreement marks the expansion of our relationship with the focus of this Agreement being to increase Eden's commercial presence in the all-important French grape and pome fruits markets. "Corteva's vast presence in France will enable Eden to capitalise on the significant commercial opportunities that exist within this expansive market and has strong potential to increase Eden's product sales revenue. Coupled with our recently received EPA approval in the US, this Agreement highlights the global demand for sustainable biopesticides and the strides Eden is making to broaden its global footprint and accelerate commercial growth." Sylvain Bedel, Managing Director of Corteva France said: "We are pleased to be expanding our working relationship with Eden by supplying to farmers Eden's innovative bio-solutions in the French market. There is a strong demand for more sustainable growing practices in France and farmers are paying increasing attention to consumer demand for such practices. Eden's unique technology helps provide a much-needed solution." |
Posted at 08/11/2024 10:40 by investingisatrickygame Alchemy,So Cavendish has a target of 20p and Eden say's in their opinion the shares are worth north of 20p. This is as of today. It doesn't take account of a full Ecovelex approval, an insecticide partner(s) and a Powdery Mildew approval in France for Esseva delivering up to 10* greater revenue than Mevalone treating Botrytis. It all adds up to a bargain share price of currently, 3.7p. So for those following the story, it offers a time to accumulate where desired and reassurance for those that are tapped out. To remind us, Ecovelex is a €33.8 million opportunity. As the Trading Update RNS stated yesterday, "However, the opportunity for the insecticide product could well surpass anything else we have done to date, and this is exciting for all of us." In other words, in my opinion, financial numbers stated in Eden presentations are likely understated. No cash needed! Question: What will Cavendish's price target be when these RNS's are delivered (expected soon according to Eden) and what will managements view of share price be at that stage? 3.7p is a ridiculous opportunity to invest in Eden with three triggers so close. |
Posted at 05/11/2024 13:29 by neutralpov Eden share price Chart indeed coiled like a spring.Aimed DOWNWARDS. Trump's impending victory in PA and elsewhere will be one of the final nails in the biocoffin of this "very bio" stock. Very bio, as in, just like faeces. |
Posted at 20/10/2024 11:26 by investingisatrickygame Alchemy said"* I was told that but how much looking ahead is being done at 3.9p?" Very, very little in my opinion, hence 3.9p! The growth in sales is down to the distributors. Eden has done its job in the respect that it has developed products that distributors want and regulators are approving. Ecovelex was required by Corteva, is required by farmers and has been jointly developed between Eden and Corteva. When that full regulatory approval comes, so will the sales, likely "in short order" :). That will be a trigger of awareness that will see 3.9p as a distant memory. Of course, before that RNS comes, an insecticide announcement could come and that could blow the bloody doors off as Michael Caine might say. So we have 2 share price triggers. Both should attract the minds of private investors, institutional investors and the press. And of course, there is the French PM/DM regulatory submission awaiting approval which will has a fast impact on revenue. Anyone of the above could within the year, put Eden into profit. Question is, how much? French approval 'could' come pre-Christmas, who knows. Corteva took control of France and Mevalone in December 2022 with regulatory label extensions due to be submitted thereafter We have been told several times that regulatory approval in the US will be more expedient now with the AI's and Sustaine already approved, so the US could be approving the insecticide ready for sale sometime in 2025 AND, Corteva has more than implied, on film, that Exovelex will be on sale in the EU in 2025. One could assume it is possible that, all 3 could make a contribution to revenue and profit in 2025. If this is understood more widely and comes to be, our share price will be, hopefully, many, many multiples of circa 4p If you view things this way, an investment in Eden now seems a total no brainer. |
Posted at 12/10/2024 13:21 by investingisatrickygame Timbo_SliceI'm sure Directors don't have endless pots of money, especially those in AIM companies; why would they. There seems to be a perception that this job status means you're loaded and can buy tens if not hundreds of thousands of pounds worth of shares at any given time. Surely that can't be true?! Options are fine as long as they are geared and aligned to shareholder success. Eden specifically is an enabler, is it not. They are enabling sales distributors to provide solutions to farmers that they themselves have not developed, at least not as successfully as they current Eden products on sale. The natural progression to that is to deepen the relationship and ask if Eden can develop other solutions to other problems. This we see happening. Eden is almost like a flower. It has been planted and is just waiting for its season to bloom and when it does, it will open up in full colour and size. This, in my opinion, is what will happen with the share price (hopefully). From nothing to something substantial. |
Posted at 08/10/2024 12:06 by money never sleeps The aptly named "Hurricane Milton" descends on Florida just as Milton Park braces itself for an Eden share price storm. |
Posted at 25/9/2024 15:40 by investingisatrickygame If you refer to Eden's presentations and add up the aggregate sales per annum over each product at peak sales within 3 years from launch, they predict circa £130 million per annum. So if they were all at 3 years, purely for illustration, and had 10 years in front of them, possibly £1.3 billion or more in salesA regulatory approval can last 10-15 years as I understand it and of course, can be renewed. Eden has a large pipeline of opportunities, they say. The Chairman stated in the half yearly report, that 'the potential for Eden is huge' The CEO said 'We anticipate the remainder of the year will provide plenty of reasons for excitement' The CFO in the Q and A re-iterated that it takes around $300 million and 10-12 years to develop a successful pesticide, yet Eden has spent £20 million to get us to where we are today (4 products if we include our insecticide), thus offering significant additional profit opportunity as there is less cost to recover. Does any of this sound like a 4p per share company? I don't think so. Does any of this sound like a 20p per share company as per the Cavendish forecast? I don't think so. 50p a share values Eden at £267 million and Eden's gross margins as highlighted by the Company themselves, provide massive headroom to run the Company and return more than 50p a share. The regulatory approved footprint alone, in my opinion is already worth a lot of money, but 'the market' doesn't seem to have caught on with where Eden are OR Eden in its communications has not reached a sufficiently big wide enough audience in order to convince more people to realise the value already in Eden. |
Posted at 24/9/2024 12:19 by jaknife Money never sleeps,You are doomed to be a losing investor, like supersonico, who is already sitting on significant Eden losses. The basic maths (and the house broker) tells you that Eden is going to lose money for 2024 and 2025. Common sense should tell you that the share price of perpetually loss-making shares always heads to zero. The share price now is 4.05p (mid), let us discuss this again when the finals come out. JakNife |
Posted at 02/9/2024 10:15 by investingisatrickygame Another layer of value added to Eden Research Plc, not yet factored into the share price.Each regulatory (new or label extension) approval adds intrinsic value to Eden, even before sales begin. As sales accumulate thereafter, further value will be attributed. Why is there intrinsic value in Eden, purely from regulatory approval? In my opinion, that is because of the 8-10 year cycle for the likes of Syngenta to bring a successfully developed product to market, $300 million and whatever time during that period, a product has been off market and no revenue have been achieved. Even this does not factor in additional cost value for unsuccessful products and time and money spent on this. The ability to view a company like Eden with a significant geographical footprint for multiple products, where substantially less money has been spent and R & D time is in the past makes Eden an attractive investment proposition and an exciting to company to partner with. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
